OnCo
ideasIdea

Population germline screening for hereditary cancer genes with cascade testing

Most people carrying a high-risk cancer gene do not know it until someone in the family gets cancer. Offer testing to all adults so carriers can be protected before that happens.

Family-history-based testing misses about half of BRCA and Lynch carriers. Population screening pilots (Ashkenazi BRCA programmes, Geisinger MyCode, Healthy Nevada) identify carriers efficiently and studies suggest cost-effectiveness at current sequencing prices. The proposal is national population screening for a defined panel of actionable hereditary cancer genes offered to all adults at a set age, with automated cascade testing offers to relatives, standardised risk-reducing pathways (enhanced surveillance, chemoprevention, risk-reducing surgery) and long-term outcome tracking.

Hypothesis
Population screening identifies at least twice as many carriers as family-history testing and reduces incidence of advanced BRCA- and Lynch-associated cancers among carriers by half within a decade.
Rationale
Carrier identification followed by proven risk reduction prevents cancers rather than treating them, and sequencing cost is now trivial relative to a single cancer treatment.
What would test it
Regional programme with randomised age-cohort rollout; endpoints carrier detection rate, uptake of risk reduction and stage at diagnosis of hereditary cancers versus unscreened regions.
Maturity
being tested at scale
Who has to act
policy
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks

Key papers

1top

Connected

10top

Pages like this

not linked directly; found by shared links